Vimarsana
Biggest News Aggregation in the World

Page 3 - Mark Lebwohl News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark Lebwohl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Lebwohl Today - Breaking & Trending Today

AMERICAN SKIN ASSOCIATION SPRING GALA CELEBRATES OUTSTANDING HONOREES - Vimarsana News

AMERICAN SKIN ASSOCIATION SPRING GALA CELEBRATES OUTSTANDING HONOREES

/PRNewswire/ -- On Tuesday evening, at The Plaza, American Skin Association (ASA) held their Spring Gala, where they presented awards to two outstanding...

Difelikefalin Helps Upper Back Itch, but With Side Effects - Vimarsana News

Difelikefalin Helps Upper Back Itch, but With Side Effects

Phase 2 results show a reduction in itch in patients with notalgia paresthetica, but 19% of patients discontinued the trial because of side effects compared with 6% in the placebo group.

New Formulation of FDA-Approved Drug Shows Encouraging Results for Treating a Common Itch Condition in Phase 2 Clinical Trial - Vimarsana News

New Formulation of FDA-Approved Drug Shows Encouraging Results for Treating a Common Itch Condition in Phase 2 Clinical Trial

New York, NY (PRWEB) February 09, 2023 -- Notalgia paresthetica—a nerve disorder characterized by a persistent itch in the upper back—is a common and

Source: prweb.com
Arcutis Presents New Phase 2 Long-Term Data Showing - Vimarsana News

Arcutis Presents New Phase 2 Long-Term Data Showing

During the open label trial, 57.1% of roflumilast-treated participants achieved Investigator Global Assessment (IGA) of clear or almost clear at any time...

Dermavant Sciences: Dermavant to Present Data from Multiple Clinical Trials of VTAMA (tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference - Vimarsana News

Dermavant Sciences: Dermavant to Present Data from Multiple Clinical Trials of VTAMA (tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference

- Five posters will highlight clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and for atopic dermatitis in patients as young as two - Dermavant Sciences, a biopharmaceutical